Breau, Rodney H.
Lavallée, Luke T.
Cnossen, Sonya
Witiuk, Kelsey
Cagiannos, Ilias
Momoli, Franco
Bryson, Gregory
Kanji, Salmaan
Morash, Christopher
Turgeon, Alexis
Zarychanski, Ryan
Mallick, Ranjeeta
Knoll, Greg
Fergusson, Dean A.
Funding for this research was provided by:
Canadian Institutes of Health Research (MOP-342559)
Article History
Received: 2 November 2017
Accepted: 3 April 2018
First Online: 2 May 2018
Ethics approval and consent to participate
: Ethics approval for the study was obtained from The Ottawa Health Science Network Research Ethics Board (Reference number: 20130151-01H).A trained research coordinator reviews the study with potential participants. Written informed consent is obtained for all eligible participants as per IHC-GCP guidelines. Participation is voluntary, and participants may withdraw from the study at any time.While the trial is ongoing, relevant parties (such as investigators, Research Ethics Board (REB), or trial participants) will be notified of any important protocol modifications (e.g., changes to eligibility criteria, consent forms, etc.).
: LTL is on Advisory Boards for Sanofi and Ferring, and has research funding and honoraria from Sanofi. CM is on Advisory Boards for AbbVie, Astellas, Sanofi, Ferring, Bayer, Janssen, and Amgen. GB is on the Editorial Board for Trials.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.